TrisPharma, Inc.

Technologies

At Tris Pharma, we have several strategic platform technologies that offer our customers many benefits. Our technologies can be leveraged to:

Develop new line extensions or differentiated products (e.g. LiquiXR, ODTXR)
Create controlled release versions of drugs in both solid and liquid dosage forms
Produce dosage forms that enhance solubility/bioavailability/drug loading
Offer other advantages such as reducing the size of current dosage forms, to help improve compliance, strengthen market position, etc.

We have developed several platform technologies focusing on research and intended benefits as follows.

Controlled Release
    LiquiXR^TM - for sustained release in liquid dosage form
    PerpetuRate^TM ProRate^TM delibRate^TM - for sustained release in solid dosage form

Enhanced Solubility/Bioavailability
    Lipisol^TM - for lipophilic/insoluble drugs (log P 1 to 5) as a liquid filled soft or hard capsules
    eXol^TM - for hydrophobic drugs with a narrow window of absorption as tablets or powder filled capsules
    maxsol^TM - for lipophilic drugs (log P 4 and above) as a liquid filled in capsules

Fast Dissolve/ODT
    ODTXR^TM - For sustained release in fast disintegrating tablets

Abuse Deterrence
    NoBuse^TM - Abuse deterrence technology that makes the product resistant to prevalent drug extraction and other common abuse approaches used on conventional formulations, without the need of additional ingredients, such as antagonist naltroxene or other ingredients.

To learn more about any of these technologies, how Tris Pharma can help your organization, or for business development and licensing inquiries, please contact Peter Ciano (pciano@trispharma.com).